Navigation Links
Accelr8 Announces Results of 2012 Annual Meeting
Date:12/13/2012

DENVER, Dec. 13, 2012 /PRNewswire/ -- Accelr8 Technology Corporation (NYSE MKT: AXK) announced today the results of its 2012 Annual Meeting of Shareholders, which was held on Wednesday, December 12, 2012.  At the Annual Meeting, shareholders re-elected Lawrence Mehren, John Patience, Jack Schuler and Matthew Strobeck, Ph.D. as directors of the Company.  Proposals to reincorporate the Company in Delaware, change the Company's name to "Accelerate Diagnostics, Inc.", approve a new Certificate of Incorporation, approve a new Omnibus Equity Incentive Plan, and ratify the selection of Comiskey & Company, P.C. as the Company's independent auditors for the upcoming fiscal year were also approved by shareholders.

The Company plans to file documents with the Delaware and Colorado Secretaries of State to complete the reincorporation in Delaware and the name change described above as soon as possible. 

For more information about the proposals that were approved by the Company's shareholders at the Annual Meeting, refer to the Definitive Proxy Statement that the Company filed with the Securities and Exchange Commission on November 13, 2012, which is available at www.sec.gov.

About Accelr8
Accelr8 Technology Corporation is focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.  The Company's BACcel™ platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that decrease time to result while maintaining high sensitivity and specificity. 

Disclaimer Regarding Forward-Looking Statements
Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the Company's filings with the SEC.  The Company does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.


'/>"/>
SOURCE Accelr8 Technology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. Accelr8 Appoints Steve Reichling Chief Financial Officer
3. OncoSec Medical Announces $7.2 Million Public Offering
4. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
5. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
6. CVS Caremark Provides Strong Growth Outlook for 2013 and Beyond, Announces 38%Dividend Increase and Outlines Strategic Growth Framework
7. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
8. Mylan Announces Pricing of Senior Notes
9. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
10. Alere Inc. Announces Hiring of Namal Nawana as Chief Operating Officer
11. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):